U.S.-China Program for Biomedical Collaborative Research (R01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively.  U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.     


  • Letter of Intent Due Date: 30 days prior to the application
  • Application Due Date(s): February 21, 2019
  • AIDS Application Due Date(s): February 21, 2019

RFA-CA-19-009 Expiration Date February 22, 2019

Agency Website

Eligibility Requirements

 Note: The Chinese collaborators must not be designated as PDs/PIs on the application in response to this FOA. 



Amount Description

Application budgets are limited to $150,000 annually in direct costs.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

    Funding Type





    Environmental & Life Sciences
    International Opportunities
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    February 21, 2019